What does this research mean for the field?

Host immune responses to donor microbiota in inflammatory bowel disease are highly individualized, suggesting that personalized donor-recipient immune compatibility assessed via an ex vivo platform is a key determinant of faecal microbiota transplantation efficacy. Novelty: ClaimNovelty.METHODOLOGICAL. Consensus alignment: ConsensusAlignment.CHALLENGES_CONSENSUS.

What question did this study set out to answer?

To determine whether recipient-specific immune responses to donor microbiota can be used to establish a personalized donor-recipient matching strategy for fecal microbiota transplantation in inflammatory bowel disease.

September 10, 2026EBioMedicineOpen Access

A functional immune-based platform for donor-recipient matching in faecal microbiota transplantation for inflammatory bowel disease

View Full Paper

Ask AI

Bookmark

Authors

CAChiara Amoroso FSFrancesco Strati PMPaola Maragno

Discussion

Member takes

Overview

Ex vivo proof-of-concept study reveals individualized immune responses to donor microbiota in inflammatory bowel disease, suggesting personalized matching could optimize transplant efficacy.

Key Points

To determine whether recipient-specific immune responses to donor microbiota can be used to establish a personalized donor-recipient matching strategy for fecal microbiota transplantation in inflammatory bowel disease.
Developed an ex vivo proof-of-concept assay termed the Gut Microbiota-Leukocyte Reaction (GMLR).
Exposed lamina propria mononuclear cells isolated from intestinal biopsies of recipients with inflammatory bowel disease to healthy donor microbiota and measured disease-associated cytokines.
Donor microbiota segregated into distinct clusters with differential immune signatures, significantly inducing IL-22 (p = 0.033) and showing a non-significant trend toward IL-17 reduction (p = 0.054).
Immune responses demonstrated substantial inter-patient variability across recipients, which enabled the generation of an algorithmic scoring framework to prioritize compatible donor-recipient pairs.

Cite This Study

Amoroso et al. (2026) studied this question.

synapsesocial.com/papers/6aa27a5658559d80afc72eb8 https://doi.org/10.1016/j.ebiom.2026.106475

View Full Paper

Ask AI

Bookmark

September 10, 2026EBioMedicineOpen Access

A functional immune-based platform for donor-recipient matching in faecal microbiota transplantation for inflammatory bowel disease

View Full Paper

Ask AI

Bookmark

Authors

CAChiara Amoroso FSFrancesco Strati PMPaola Maragno

Discussion

Member takes

Overview

Ex vivo proof-of-concept study reveals individualized immune responses to donor microbiota in inflammatory bowel disease, suggesting personalized matching could optimize transplant efficacy.

Key Points

To determine whether recipient-specific immune responses to donor microbiota can be used to establish a personalized donor-recipient matching strategy for fecal microbiota transplantation in inflammatory bowel disease.
Developed an ex vivo proof-of-concept assay termed the Gut Microbiota-Leukocyte Reaction (GMLR).
Exposed lamina propria mononuclear cells isolated from intestinal biopsies of recipients with inflammatory bowel disease to healthy donor microbiota and measured disease-associated cytokines.
Donor microbiota segregated into distinct clusters with differential immune signatures, significantly inducing IL-22 (p = 0.033) and showing a non-significant trend toward IL-17 reduction (p = 0.054).
Immune responses demonstrated substantial inter-patient variability across recipients, which enabled the generation of an algorithmic scoring framework to prioritize compatible donor-recipient pairs.

Cite This Study

Amoroso et al. (2026) studied this question.

synapsesocial.com/papers/6aa27a5658559d80afc72eb8 https://doi.org/10.1016/j.ebiom.2026.106475

View Full Paper

Ask AI

Bookmark